Nuvilex, Inc.'s Phase III Pancreatic Cancer Trials Could Address New Law's Call for Progress

NEW YORK, NY--(Marketwired - Jun 24, 2013) - Nuvilex, Inc. (OTCQB: NVLX) has a great opportunity to demonstrate and showcase its encapsulation technology in its upcoming Phase III clinical trials for the treatment of late stage, inoperable pancreatic cancer. There will be plenty of interested observers, and you can bet lawmakers in Washington responsible for the Recalcitrant Cancer Research Act that was signed into law earlier this year, will be among them.

Nuvilex's upcoming late stage trials could be just what this Act is striving for -- a more successful treatment than the current standard, and a sign of progress against pancreatic cancer. Originally introduced as the Pancreatic Cancer Research and Education Act, the Recalcitrant Cancer Research Act became law on January 2, 2013, as part of the National Defense Authorization Act. The law calls on the National Cancer Institute (NCI) to develop scientific frameworks that will help provide the strategic direction and guidance needed to make true progress against pancreatic and lung cancers by July 2014. 

Under the statute, the NCI Director may also develop scientific frameworks for other deadly or recalcitrant cancers, defined as those with a five-year relative survival rate below 50 percent. Nuvilex, of course, is heavily invested in pancreatic cancer research. Pancreatic cancer is one of the deadliest cancers with only a five-year survival rate of just 6%. Survival rates for pancreatic cancer have remained in the single digits for nearly forty years.

Dr. Gerald Crabtree, Nuvilex's COO, stated, "This new Act serves to shine a spotlight on the still evident devastating and deadly nature of pancreatic cancer, particularly when it is at an advanced stage and when it is inoperable, and the fact that improvements in its treatment over the past few years have been relatively minor. We at Nuvilex fervently hope that, if successful, our live-cell encapsulation-based treatment will be a quantum leap forward in the satisfactory treatment of this disease."

Continue reading at www.stockmarketmediagroup.com/features.

About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors to become better informed on small cap companies. For more information: www.stockmarketmediagroup.com